FDA Approves First Pure Hydrocodone Drug With Abuse-Deterrent Properties

FDA approved the first single-entity extended-release hydrocodone product that has abuse-deterrent properties, unlike the controversial drug Zohydro that received push-back from lawmakers and consumer advocates who are concerned about preventing opioid overdose. The drug, Purdue Pharma's Hysingla ER, will deter patients from abusing the therapy via chewing, snorting and injection, but abuse through intravenous, intranasal and oral routes is still possible. FDA's Center for Drug Evaluation and Research Director Janet Woodcock describes the approval as a mark of additional progress...